TY - JOUR
T1 - Investigation of glial fibrillary acidic protein (GFAP) in body fluids as a potential biomarker for glioma
T2 - a systematic review and meta-analysis
AU - van Asperen, Jessy V.
AU - Fedorushkova, Daria M.
AU - Robe, Pierre A.J.T.
AU - Hol, Elly M.
N1 - Funding Information:
This research was funded by the Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding (KWF), grant number 10123 and the T. and P. Bohnenn Foundation. All authors reviewed and approved the manuscript before submission. We would like to thank Isabel Retel Helmrich for her valuable feedback concerning the data analysis. We would like to acknowledge the KWF for funding.
Funding Information:
All authors reviewed and approved the manuscript before submission. We would like to thank Isabel Retel Helmrich for her valuable feedback concerning the data analysis. We would like to acknowledge the KWF for funding.
Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022/1/2
Y1 - 2022/1/2
N2 - Introduction: Liquid biopsies are promising diagnostic tools for glioma. In this quantitative systematic review, we investigate whether the detection of intermediate filaments (IF) in body fluids can be used as a tool for glioma diagnosis and prognosis. Materials and methods: We included all studies in which IF-levels were determined in patients with glioma and healthy controls. Of the 28 identified eligible studies, 12 focussed on levels of GFAP in serum (sGFAP) and were included for metadata analysis. Results: In all studies combined, 62.7% of all grade-IV patients had detectable levels of sGFAP compared to 12.7% of healthy controls. sGFAP did not surpass the limit of detection in lower-grade patients or healthy controls, but sGFAP was significantly elevated in grade-IV glioma (0.12 ng/mL (0.06 − 0.18), P < 0.001) and showed an average median difference of 0.15 ng/mL (0.04 − 0.25, P < 0.01) compared to healthy controls. sGFAP levels were linked to tumour volume, but not to patient outcome. Conclusion: The presence of sGFAP is indicative of grade-IV glioma, but additional studies are necessary to fully determine the usefulness of GFAP in body fluids as a tool for grade-IV glioma diagnosis and follow-up.
AB - Introduction: Liquid biopsies are promising diagnostic tools for glioma. In this quantitative systematic review, we investigate whether the detection of intermediate filaments (IF) in body fluids can be used as a tool for glioma diagnosis and prognosis. Materials and methods: We included all studies in which IF-levels were determined in patients with glioma and healthy controls. Of the 28 identified eligible studies, 12 focussed on levels of GFAP in serum (sGFAP) and were included for metadata analysis. Results: In all studies combined, 62.7% of all grade-IV patients had detectable levels of sGFAP compared to 12.7% of healthy controls. sGFAP did not surpass the limit of detection in lower-grade patients or healthy controls, but sGFAP was significantly elevated in grade-IV glioma (0.12 ng/mL (0.06 − 0.18), P < 0.001) and showed an average median difference of 0.15 ng/mL (0.04 − 0.25, P < 0.01) compared to healthy controls. sGFAP levels were linked to tumour volume, but not to patient outcome. Conclusion: The presence of sGFAP is indicative of grade-IV glioma, but additional studies are necessary to fully determine the usefulness of GFAP in body fluids as a tool for grade-IV glioma diagnosis and follow-up.
KW - biomarker
KW - blood serum
KW - cytoskeleton
KW - GFAP
KW - Glioblastoma multiforme
KW - intermediate filament
UR - http://www.scopus.com/inward/record.url?scp=85120639181&partnerID=8YFLogxK
U2 - 10.1080/1354750X.2021.2006313
DO - 10.1080/1354750X.2021.2006313
M3 - Review article
AN - SCOPUS:85120639181
SN - 1354-750X
VL - 27
SP - 1
EP - 12
JO - Biomarkers
JF - Biomarkers
IS - 1
ER -